Top

International Journal of Legal Medicine

Published in:

01-03-2011 | Original Article

Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users

Authors: Anu M. Neuvonen, Jukka U. Palo, Antti Sajantila

Published in: International Journal of Legal Medicine | Issue 2/2011

Abstract

Background

P-glycoprotein, a common transporter molecule, is known to affect metabolic functions in humans. Polymorphisms of the multidrug resistance gene (ABCB1/MDR1) coding for P-glycoprotein have been linked to changes in the processing of several commonly used medications in patients. Here, we have evaluated the impact of ABCB1 single nucleotide polymorphisms on digoxin fatality, through investigation of the relationship between post-mortem digoxin concentration and ABCB1 genotype.

Methods

The effect of three ABCB1 single nucleotide polymorphisms (SNPs) (3435C>T, 1236C>T, and 2677G>T) on digoxin concentration was examined in 112 deceased Finnish subjects through RT-PCR genotyping of post-mortem blood samples. These subjects were selected on the basis of digoxin findings during the post-mortem toxicology screen, and categorized by digoxin concentration into three distinct groups. The distributions of mutant alleles and haplotypes in the deceased were compared to a random sample of 143 Finns.

Results

Mutant genotype frequencies showed a positive relationship with post-mortem digoxin concentration for all SNPs. Female subjects showed a more emphatic pattern, suggesting a higher risk of digoxin intoxication.

Conclusions

These findings demonstrate a link between ABCB1 polymorphisms and increased mortality, and suggest that individualized genotyping should be considered prior to digoxin treatment. This research also exemplifies the value of gender-segregated genotyping studies in helping establish drug safety parameters, while allowing more decisive determination of cause and manner of death in a medico-legal context.

The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 336(8):525–533CrossRef

Launiainen T, Vuori E, Ojanperä I (2009) Prevalence of adverse drug combinations in a large post-mortem toxicology database. Int J Legal Med 123(2):109–115PubMedCrossRef

Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84(21):7735–7738PubMedCrossRef

Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473–3478PubMedCrossRef

Sakaeda T, Nakamura T, Horinouchi M et al (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18(10):1400–1404PubMedCrossRef

Johne A, Köpke K, Gerloff T et al (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein ABCB1 gene. Clin Pharmacol Ther 72(5):584–594PubMedCrossRef

Verstuyft C, Schwab M, Schaeffeler E et al (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58(12):809–812PubMed

Morita Y, Sakaeda T, Horinouchi M (2003) MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 20(4):552–556PubMedCrossRef

Chowbay B, Li H, David M, Cheung YB, Lee EJD (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Brit J Clin Pharmacol 60(2):159–171CrossRef

10.

Aarnoudse AJ, Dieleman JP, Visser LE et al (2008) Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 18(4):299–305PubMedCrossRef

11.

Böttiger Y, Laine K, Andersson ML et al (2009) SFINX–a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65(6):627–633PubMedCrossRef

12.

PHASE software for haplotype estimation. Accessed April 2010, at http://stephenlab.uchicago.edu/software.html

13.

Excoffier L, Laval G, Schneider S (2005) Arlequin ver. 3.0: an integrated software package for population genetics data analysis. Evol Bioinform Online 1:47–50PubMed

14.

Lao O, Lu TT, Nothnagel M et al (2008) Correlation between genetic and geographic structure in Europe. Curr Biol 18(16):1241–1248PubMedCrossRef

15.

Keskitalo JE, Kurkinen KJ, Neuvonen PJ, Niemi M (2008) ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84(4):457–461PubMedCrossRef

16.

Palo JU, Hedman M, Ulmanen I, Lukka M, Sajantila A (2007) High degree of Y-chromosomal divergence within Finland—forensic aspects. Forensic Sci Int-Gen 1:120–124CrossRef

17.

Salmela E, Lappalainen T, Fransson I et al (2008) Genome-wide analysis of single nucleotide polymorphisms uncovers population structure in Northern Europe. PLoS ONE 3(10):e3519PubMedCrossRef

18.

Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347(18):1403–1411PubMedCrossRef

19.

Aarnoudse AL, Dieleman JP, Stricker BH (2007) Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30(5):431–436PubMedCrossRef

20.

Nicolson TJ, Mellor HR, Roberts RRA (2009) Gender differences in drug toxicity. Trends Pharmacol Sci 31(3):108–114CrossRef

21.

Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275(2):1011–1018PubMed

22.

Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82(1):87–96PubMedCrossRef

23.

Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59(4):303–312PubMedCrossRef

24.

Goreva OB, Grishanova AY, Domnikova NP, Mukhin OV, Lyakhovich VV (2004) MDR1 gene C1236T and C6+139T polymorphisms in the Russian population: associations with predisposition to lymphoproliferative diseases and drug resistance. Bull Exp Biol Med 138(4):404–406PubMed

25.

Green H, Söderkvist P, Rosenberg P, Horvath G, Peterson C (2006) MDR1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12(3):854–859PubMedCrossRef

26.

Larsen UL, Hyldahl Olesen L, Guldborg-Nyvold C et al (2007) Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 67(2):123–134PubMedCrossRef

27.

Pechandova K, Buzkova H, Slanar O, Perlik F (2006) Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha) 52(6):184–189

28.

Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL (2007) MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev 16(6):1172–1177CrossRef

29.

Song P, Lamba JK, Zhang L et al (2006) G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 46(3):373–379PubMedCrossRef

30.

Gonzalez TP, Mucenic T, Brenol JCT, Xavier RM, Scheingold M, Chies JAB (2008) ABCB1 C1236T, G2677T/A, and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res 41(9):769–772PubMedCrossRef

31.

Chelule PK, Gordon M, Palanee T, Mosam A, Coovadia HM, Cassol S (2003) MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther 74(2):195–196PubMedCrossRef

32.

Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11(3):217–221PubMedCrossRef

33.

Chen B, Fang J, Zhang W, Jin Z, Yu Z, Cai W (2009) Detection of C1236T, G2677T, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J Clin Lab Anal 23(2):110–116PubMedCrossRef

34.

Komoto C, Nakamura T, Sakaeda T et al (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21(2):126–132PubMedCrossRef

35.

Ryu HC, Kwon HY, Choi IK, Rhee DK (2006) Analyses of single nucleotide polymorphisms and haplotype linkage of the human ABCB1 (MDR1) gene in Korean. Arch Pharm Res 29(12):1132–1139PubMedCrossRef

Title: Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users
Authors: Anu M. Neuvonen
Jukka U. Palo
Antti Sajantila
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: International Journal of Legal Medicine / Issue 2/2011
Print ISSN: 0937-9827
Electronic ISSN: 1437-1596
DOI: https://doi.org/10.1007/s00414-011-0550-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

Chronological age estimation based on third molar development in a Portuguese population

Fourteen non-CODIS autosomal short tandem repeat loci multiplex data from Taiwanese

Petechial bleedings in sudden infant death

Accuracy of predicting 18 years of age from mandibular third molar development in an Indian sample using Demirjian’s ten-stage criteria

Odontometric sex assessment from logistic regression analysis

Accuracy of Cameriere, Haavikko, and Willems radiographic methods on age estimation on Bosnian–Herzegovian children age groups 6–13